Table 2 Characteristics of non-QAACT available in the public sector during the most recent survey round
Kinshasa, DRC 2015 | Katanga DRC 2015 | Nigeria 2015 | Kenya 2014 | Tanzania 2014 | Uganda 2015 | Zambia 2014 | |
|---|---|---|---|---|---|---|---|
% (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) | |
N = 390 | N = 148 | N = 96 | N = 50 | N = 58 | N = 59 | N = 941 | |
Active ingredients (type) | |||||||
Artemether lumefantrine | 75.0 (69.9–79.5) | 76.8 (66.1, 84.9) | 76.2 (52.7, 90.2) | 44.2 (23.4, 67.3) | 52.6 (33.1, 71.4) | 37.6 (22.1, 56.2) | 100.0 (99.8, 100.0) |
Artesunate amodiaquine | 4.9 (3.1, 7.9) | 10.5 (3.9, 25.3) | 8.3 (1.6, 33.0) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) |
Artesunate mefloquine | 0.0 (–) | 0.0 (–) | 0.3 (<0.1, 2.2) | 0.3 (0.1, 1.0) | 5.0 (1.2, 18.0) | 0.0 (–) | 0.0 (–) |
Artemisinin piperaquine | 1.2 (0.3, 4.5) | 1.6 (0.5, 4.9) | 0.0 (–) | 6.4 (2.8, 13.9) | 2.5 (1.0, 6.3) | 0.0 (–) | 0.0 |
Artemisinin naphthoquine | 0.9 (0.1, 6.1) | 0.0 (–) | 0.0 (–) | 6.2 (2.6, 13.9) | 0.0 (–) | 19.0 (7.7, 39.7) | 0.0 (–) |
Artesunate SP | 5.1 (3.3, 7.9) | 5.5 (2.9, 10.3) | 3.2 (0.5, 18.8) | 0.8 (0.2, 3.0) | 0.0 (–) | 0.0 (–) | 0.1 (<0.1, 0.2) |
Dihydroartemisinin piperaquine | 12.1 (8.2, 17.3) | 2.1 (0.9, 4.7) | 12.0 (4.4, 28.7) | 42.1 (26.1, 59.9) | 39.9 (22.0, 61.0) | 43.0 (26.1, 61.6) | 0.0 (–) |
Dihydroartemisinin SP | 0.8 (0.4, 1.8) | 3.5 (0.9, 12.3) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) |
Arterolane piperaquine | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.0 (–) | 0.4 (0.1, 2.6) | 0.0 (–) |
Product formulation | |||||||
Tablet | 56.5 (48.0, 64.7) | 70.0 (61.4, 77.3) | 61.0 (41.9, 77.2) | 77.1 (64.5, 86.2) | 91.5 (78.6, 96.9) | 87.3 (74.7, 94.1) | 99.6 (99.0, 99.8) |
Suspension | 43.5 (35.3, 52.0) | 30.0 (22.7, 38.6) | 38.1 (22.1, 57.2) | 22.9 (13.8, 35.5) | 7.6 (2.6, 20.1) | 12.8 (5.9, 25.3) | 0.4 (0.2, 1.0) |
Granule | 0.0 (–) | 0.0 (–) | 0.9 (0.1, 7.0) | 0.0 (–) | 0.9 (0.1, 5.6) | 0.0 (–) | 0.0 (–) |
N = 384 | N = 145 | N = 96 | N = 50 | N = 54 | N = 59 | N = 939 | |
|---|---|---|---|---|---|---|---|
Country of manufacturea | |||||||
Local | 25.6 (19.8, 32.4) | 23.7 (15.9, 33.7) | 17.1 (5.2, 43.5) | 14.8 (7.1, 28.2) | 1.1 (0.2, 6.6) | 0.0 (–) | 0.0 (–) |
India | 62.7 (57.2, 67.8) | 69.7 (59.7, 78.1) | 61.5 (42.8, 77.3) | 58.8 (40.5, 75.0) | 35.3 (18.2, 57.2) | 37.7 (21.9, 56.5) | 99.9 (99.7, 100.0) |
China | 2.4 (0.9, 6.6) | 1.8 (0.6, 5.7) | 19.0 (7.9, 39.0) | 16.7 (8.7, 29.5) | 47.3 (27.7, 67.7) | 54.1 (33.9, 73.0) | 0.0 (–) |
European Country | 3.4 (2.0, 5.6) | 2.9 (1.3, 6.4) | 0.3 (< 0.1, 2.2) | 9.7 (5.5, 16.6) | 16.3 (6.4, 35.6) | 8.3 (2.8, 22.0) | 0.1 (< 0.1, 0.4) |
Otherb | 6.0 (2.7, 12.8) | 1.9 (0.4, 9.3) | 2.2 (0.4, 12.1) | 0.0 (–) | 0.0 (0) | 0.0 (–) | 0.0 (–) |
Registered with the National Drug Regulatory Authority | 52.8 (44.0, 61.4) | 19.3 (13.2, 27.2) | 48.5 (26.9, 70.6) | 33.6 (21.5, 48.2) | n/a | 63.2 (43.5, 79.2) | 1.6 (0.9, 3.0) |